Omnicell, Inc. (OMCL) recently announced Central Med Automation Service, a subscription-based solution. It is designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers ("CPSCs") and similar operations. About Central Med Automation Service Intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, this solution is expected to improve inventory visibility, sc ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $277 million, a sequential increase of $31 million or 12% over the prior quarter, but a decrease of $22 million or 7% compared to Q2 2023 [7][18] - GAAP earnings per share for Q2 2024 were $0.08, compared to a loss of $0.34 in the prior quarter and a profit of $0.08 in Q2 2023 [7][20] - Non-GAAP earnings per share for Q2 2024 were $0.51, compared to $0.03 in the prior quarter and $0.57 in the same period last year [21] - Non-GAAP EBITDA for Q2 2024 was $40 million, an increase of $29 million compared to the previous quarter, but a decrease of $7 million compared to the same period last year [21] Business Line Data and Key Metrics Changes - Product revenues were $157 million, an increase of 17% over the previous quarter but down 17% compared to Q2 2023 [19] - Services revenues were $120 million, an increase of 7% over the previous quarter and an increase of 9% compared to Q2 2023 [19] - Advanced Services represented 22% of total revenue for the first and second quarters of 2024, up from 18% in Q2 2023 [10] Market Data and Key Metrics Changes - The macroeconomic landscape is showing early signs of improvement, with demand for medication management solutions tracking in line with expectations [6][18] - The company anticipates total recurring revenue, including Consumables and Technical Services, to represent approximately 50% of total revenue for the full year 2024 [10][52] Company Strategy and Development Direction - The company is focusing on innovations around its XT platform and offering services expected to increase recurring revenue [5][6] - The XT Amplify program aims to maximize value for healthcare facilities and drive enhanced clinical and operational outcomes [8][9] - The company is committed to prudent expense management while rolling out its innovation agenda [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver consistent performance and improve financial results [5][6] - The demand environment is expected to remain strong, particularly for Specialty Pharmacy Services and point-of-care products [18][28] - Management noted that health systems are expanding, indicating a healthy financial position for customers [71] Other Important Information - The company is updating its full-year 2024 guidance based on strong first-half performance and current visibility [23] - For full-year 2024, total revenues are expected to be in the range of $1.070 billion to $1.110 billion [23] Q&A Session Summary Question: What drove the beat in product revenue for Q2 and what contributed to the guidance revision? - The beat was driven by strong demand in the point-of-care product portfolio and Specialty Pharmacy Services, while the guidance revision reflects implementation schedules and visibility into the second half [28][29] Question: Can you size the cost-saving opportunities identified in the holistic review? - The company expects continued improvement in performance and cost savings through prudent expense management [30] Question: How is the demand environment for compounding and Central Pharmacy Robotics Solutions? - There is significant interest, but deployment is slower as features are adjusted to meet new regulations [32] Question: Can you provide more color on the XT Amplify program and its impact on guidance? - XT Amplify is expected to build backlog but will not significantly contribute to revenues this year; most bookings will hit next year [35] Question: What is the current pricing environment for product revenues? - There have been no major changes in pricing, and the company remains disciplined in its approach [62] Question: How do improving labor trends impact the revenue outlook? - Improved labor availability allows for more efficient installations and customer confidence in implementing systems [59]

Omnicell, Inc. (OMCL) reported second-quarter 2024 adjusted earnings per share (EPS) of 51 cents, which declined 10.5% year over year. However, the metric beat the Zacks Consensus Estimate of 16 cents by a stupendous 218%. Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, RDS restructuring and others. GAAP EPS was 8 cents, flat year over year. Revenues in Detail Revenues totaled $276.8 million, down 7.4% year over ye ...

Omnicell (OMCL) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 218.75%. A quarter ago, it was expected that this Omnicell Inc. Would post a loss of $0.08 per share when it actually produced earnings of $0.03, delivering a surprise of 137.50%. Over the last four quarters, the company ...

Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Omnicell would post a loss of $0.08 per share when it actually produced earnings of $0.03, delivering a surprise of +137.50%. Over the last four quarters, the ...

The renowned healthcare technology company has a market capitalization of $1.36 billion. Omnicell surpassed estimates in each of the trailing four quarters, delivering an average negative earnings surprise of 93.2%. Image Source: Zacks Investment Research Macro Concerns Put Pressure on the Bottom Line: Myriad Genetics has been grappling with escalated expenses for a while. Deteriorating international trade, global inflationary pressure leading to a tough situation Estimate Trend Some better-ranked stocks in ...

Omnicell (OMCL) has been gaining from the successful execution of its growth strategies. Yet, macroeconomic concerns continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently. Omnicell strategizes to offer differentiated, innovative solutions, expand into new markets and grow through strategic partnerships and acquisition of new technologies. The company successfully increased its installed base of Point of Care connected devices through market share gains in the past three years. In 202 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Omnicell, Inc. (OMCL) reported first-quarter 2024 adjusted earnings per share (EPS) of 3 cents compared with 39 cents in the year-ago quarter. However, the metric beat the Zacks Consensus Estimate of a loss of 8 cents per share.Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, executive transition costs, severance-related expenses and others.GAAP loss was 34 cents per share in the quarter under review compared with 3 ...

May 2, 2024 This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including Q1-2024 non-GAAP gross margin, non-GAAP operating expense, nonGAAP EBITDA, and non-GAAP earnings per share, 2017 and Q1-2024 liquidity and 2017 and Q1-2024 net debt/EBITDA, guidance with respect to 2024 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and Q1-2024 non-GAAP financial measures to the most directly comp ...